Compare · MDLN vs TELA
MDLN vs TELA
Side-by-side comparison of Medline Inc. (MDLN) and TELA Bio Inc. (TELA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and TELA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $52.27B, about 1597.3x TELA ($32.7M).
- Over the past year, MDLN is down 2.3% and TELA is down 65.9% - MDLN leads by 63.6 points.
- MDLN has been more active in the news (4 items in the past 4 weeks vs 2 for TELA).
- MDLN has more recent analyst coverage (25 ratings vs 2 for TELA).
- Company
- Medline Inc.
- TELA Bio Inc.
- Price
- -
- -
- Market cap
- $52.27B
- $32.7M
- 1M return
- +7.36%
- -19.66%
- 1Y return
- -2.33%
- -65.89%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2019
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 2
TELA Bio Inc.
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
Latest TELA
- Director Plovanic William J. was granted 20,930 shares, increasing direct ownership by 89% to 44,530 units (SEC Form 4)
- Director Capper Joseph H was granted 6,227 shares, increasing direct ownership by 26% to 29,827 units (SEC Form 4)
- Director Rocchio Betty Jo was granted 11,675 shares, increasing direct ownership by 98% to 23,600 units (SEC Form 4)
- Director Capper Joseph H was granted 23,600 shares (SEC Form 4)
- SEC Form 3 filed by new insider Capper Joseph H
- Director Plovanic William J. was granted 11,675 shares, increasing direct ownership by 98% to 23,600 units (SEC Form 4)
- SEC Form 3 filed by new insider Neels Guido J
- Director Neels Guido J was granted 23,600 shares (SEC Form 4)
- SEC Form 3 filed by new insider Thomas Paul
- Director Thomas Paul was granted 23,600 shares (SEC Form 4)